Company intelligence / Profile preview

Anosys

Santa Monica / general California presence, California, United Statesanosys.tech ↗

Ownership: Private
Development stage: Other

Overview

Anosys developed an exosome-based immunotherapy platform targeting cancer. Their lead program used autologous dexosomes to stimulate immune responses against tumor antigens in patients with advanced cancers such as melanoma and NSCLC. Early-phase trials showed promising safety and some efficacy signals, but the most recent clinical trial for Stage IV melanoma was suspended and there are no active programs as of mid-2025.

Therapeutic areas: Oncology
Modalities: Exosome-based therapyCell-derived vesicle therapy
Industry: Biotech

Partnerships

Licensed core IP from INSERM France, Gustave-Roussy Institute France, Curie Institute France

Beyond the preview

Go deeper on Anosys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anosys.

Explore the full profile